Olivier Bogillot, president of Sanofi France, told Francetvinfo that his vaccine would be put into circulation by mid-2021, if the results of phase 3 of its ongoing clinical trial are conclusive. A promise that the French pharmaceutical group had already formulated in June 2020, with the key to up to one billion doses per year.